FDA Says ADHD Medication Adderall Is in Short Supply
THURSDAY, Oct. 13, 2022 (HealthDay News) -- People with attention-deficit/hyperactivity disorder (ADHD) or narcolepsy may rely on the drug Adderall, but it is in short supply, the U.S. Food and Drug Administration announced Wednesday.
The Adderall and Adderall IR shortage is due to intermittent manufacturing delays at Teva, one of the companies that produces the medication. While other companies continue to produce these amphetamine mixed salts, they do not make enough to meet U.S. demand.
Adderall is FDA-approved for ADHD and narcolepsy. Until supply is restored, alternatives include the extended-release version of amphetamine mixed salts, the FDA said.
The FDA has posted information online on current manufacturers and available product strengths. It is monitoring the shortage and helping manufacturers get what they need to resolve it. The agency said it would continue to provide updates.
Patients should work with their doctors to determine their best treatment option, according to a news release from the FDA Center for Drug Evaluation and Research.
Related Posts
Los tratamientos de fertilidad no son peligrosos para las personas con EM
JUEVES, 16 de marzo de 2023 (HealthDay News) -- Las mujeres que sufren de...
New Cancer Diagnosis May Up Risk for CV Death, Morbidity
TUESDAY, March 15, 2022 (HealthDay News) -- New cancer diagnosis is associated...
Supervised Walking Program Benefits Veterans Admitted to Hospital
TUESDAY, June 6, 2023 (HealthDay News) -- For veterans admitted to the...
Vaping Can Hamper Breathing in the Young
WEDNESDAY, Aug. 16, 2023 (HealthDay News) -- When teens vape, their lungs pay a...